OnKure Therapeutics (OKUR) Institutional Ownership $2.49 -0.02 (-0.80%) Closing price 04:00 PM EasternExtended Trading$2.50 +0.01 (+0.56%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for OnKure Therapeutics (NASDAQ:OKUR)CurrentInstitutional OwnershipPercentage90.98%Number ofInstitutional Buyers(last 12 months)32TotalInstitutional Inflows(last 12 months)$65.10MNumber ofInstitutional Sellers(last 12 months)0 Get OKUR Insider Trade Alerts Want to know when executives and insiders are buying or selling OnKure Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data OKUR Institutional Buying and Selling by Quarter OnKure Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025ADAR1 Capital Management LLC10,000$43K0.0%N/A0.074% 5/14/2025Affinity Asset Advisors LLC394,159$1.70M0.2%+173.4%2.934% 2/17/2025Vestal Point Capital LP635,000$5.46M0.3%N/A19.012% 2/17/2025Two Sigma Advisers LP14,228$122K0.0%N/A0.426% 2/17/2025Tang Capital Management LLC294,626$2.53M0.2%N/A8.821% 2/17/2025Shay Capital LLC15,016$129K0.0%N/A0.450% 2/17/2025Sphera Funds Management LTD.87,354$751K0.1%N/A2.615% 2/17/2025Prosight Management LP63,754$548K0.2%N/A1.909% 2/17/2025OMERS ADMINISTRATION Corp12,100$104K0.0%N/A0.362% 2/17/2025NEA Management Company LLC478,548$4.12M0.2%N/A14.328% Get the Latest News and Ratings for OKUR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025Millennium Management LLC144,099$1.24M0.0%N/A4.314% 2/17/2025Deep Track Capital LP523,989$4.51M0.2%N/A15.688% 2/17/2025Cubist Systematic Strategies LLC20,549$177K0.0%N/A0.615% 2/17/2025Cantor Fitzgerald L. P.35,700$294K0.0%N/A1.069% 2/17/2025Citadel Advisors LLC1,074,314$8.78M0.0%N/A32.165% 2/17/2025Bank of America Corp DE249,642$2.15M0.0%N/A7.474% 2/17/2025683 Capital Management LLC43,371$373K0.0%N/A1.299% 2/17/2025Acorn Capital Advisors LLC1,439,674$12.38M6.8%N/A43.104% 2/14/2025Samsara BioCapital LLC824,155$7.09M1.0%N/A24.675% 2/14/2025Nantahala Capital Management LLC54,777$471K0.0%N/A1.640% 2/14/2025Northern Trust Corp19,177$165K0.0%N/A0.574% 2/14/2025Boothbay Fund Management LLC78,021$671K0.0%N/A2.336% 2/14/2025Altium Capital Management LLC218,386$1.88M0.5%N/A6.539% 2/13/2025Affinity Asset Advisors LLC144,159$1.24M0.2%N/A4.316% 2/13/2025Carlyle Group Inc.269,895$2.33M0.5%N/A8.081% 2/13/2025Walleye Capital LLC13,495$116K0.0%N/A0.404% 2/13/2025XTX Topco Ltd18,633$160K0.0%N/A0.558% 2/13/2025Barclays PLC8,741$75K0.0%N/A0.262% 2/13/2025Renaissance Technologies LLC47,450$408K0.0%N/A1.421% 2/12/2025Aldebaran Capital LLC45,572$392K0.4%N/A1.363% 2/12/2025Aisling Capital Management LP88,607$762K0.3%N/A2.651% 2/12/2025Geode Capital Management LLC76,599$659K0.0%N/A2.291% 2/12/2025Highbridge Capital Management LLC399,743$3.44M0.1%N/A11.958% (Data available from 1/1/2016 forward) OKUR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of OKUR shares? During the previous two years, 32 institutional investors and hedge funds held shares of OnKure Therapeutics. The most heavily invested institutionals were Acorn Capital Advisors LLC ($12.38M), Citadel Advisors LLC ($8.78M), Samsara BioCapital LLC ($7.09M), Vestal Point Capital LP ($5.46M), Deep Track Capital LP ($4.51M), NEA Management Company LLC ($4.12M), and Highbridge Capital Management LLC ($3.44M).Learn more on OnKure Therapeutics' institutional investors. What percentage of OnKure Therapeutics' stock is owned by institutional investors? 90.98% of OnKure Therapeutics' stock is owned by institutional investors. Learn more on OKUR's institutional investor holdings. Which institutional investors have been buying OnKure Therapeutics' stock? Of the 32 institutional investors that purchased OnKure Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Acorn Capital Advisors LLC ($1.44M), Citadel Advisors LLC ($1.07M), Samsara BioCapital LLC ($824.16K), Vestal Point Capital LP ($635K), Deep Track Capital LP ($523.99K), NEA Management Company LLC ($478.55K), and Highbridge Capital Management LLC ($399.74K). How much institutional buying is happening at OnKure Therapeutics? Institutional investors have bought a total of 7,699,374 shares in the last 24 months. This purchase volume represents approximately $65.10M in transactions. Related Companies Fate Therapeutics Major Shareholders Caribou Biosciences Major Shareholders Cardiol Therapeutics Major Shareholders Korro Bio Major Shareholders Nkarta Major Shareholders Immuneering Major Shareholders Kyverna Therapeutics Major Shareholders Upexi Major Shareholders Protalix BioTherapeutics Major Shareholders BioHarvest Sciences Major Shareholders This page (NASDAQ:OKUR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.